II

ImageneBio Inc

IMA·NASDAQ

$5.69

+2.3%
HealthcareBiotechnology

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

At a Glance

Live Snapshot
Market Cap$64.18M
EPS-10.7600
P/E Ratio-0.53
Earnings Date07/23/2026

ima

Net Cash Provided by Financing Activities

Last Annual Value

135.47M

3-Year CAGR

398%

5-Year CAGR

3%

10-Year CAGR

%

II

ImageneBio Inc Competitors Analysis of Net Cash Provided by Financing Activities

IMA · NASDAQ
CompanyNet Cash Provided by Financing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
IMA logo
ImageneBio Inc
NASDAQ:IMA
135.47M
21.3%0.6%N/A 
-4.78M
N/AN/AN/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
75.25M
583.2%-20.9%N/A
14.89M
N/A-19.3%N/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
65.58M
298.9%8.9%18.1%
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
8.54M
59.9%2.3%47.5%
46.47M
19.0%15.7%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
4.24M
-34.7%-49.2%N/A
44.00K
-93.2%-57.7%-13.0%
75.21M
35.0%142.1%N/A
159.61M
123.8%269.4%N/A
II

ImageneBio Inc Fair Value Envelope

IMA · NASDAQ

Our analysis suggests that IMA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.69, this represents a potential HIDDEN relative to our calculated worth for ImageneBio Inc.

Intrinsic Value
Current Price: $5.69